Dwight Stapleton, MD, MMM, FACC, FACP, FACPE

  • Clinical Details
  • Education
  • News & Video
  • Clinical Trials
  • Briefs & Publications
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Cardiomyopathy
  • Cardiovascular Disease
  • Coronary Heart Disease
  • Dyslipidemia
  • Heart Failure
  • Hypertension
  • Nuclear Cardiology
  • Preventive Cardiology
  • Valvular Heart Disease
Certification: 
  • American Board of Internal Medicine
  • American Board of Internal Medicine/Cardiovascular Disease
  • Certification Board of Nuclear Cardiology
  • Level II certification in Cardiovascular Computerized Tomography and Cardiac Magnetic Resonance Imaging
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Internship: 
  • University of Washington School of Medicine, Seattle, Wash.
Residency: 
  • University of Washington School of Medicine, Seattle, Wash.
Fellowship: 
  • University of Washington School of Medicine, Seattle, Wash.
Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Principal Investigator: Stapleton M.D., Dwight
Sub-Investigator(s):
Sponsor: Sanofi Aventis
Indentifier #: NCT01663402
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey SA_EFC11570)
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Stapleton M.D., Dwight
Sponsor: Janssen
Indentifier #: NCT01877915
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure COMMANDER HF Study
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01968967
Title:
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975376
Title:
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975389
Title:
Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Sub-Investigator(s):
Sponsor: Sanofi Aventis
Indentifier #: NCT01663402
Title:
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Sponsor: Janssen
Indentifier #: NCT01877915
Title:
Department: Cardiology
Diagnosis: Miscellaneous
Sub-Investigator(s):
Sponsor: Synageva
Indentifier #: NCT02112994
Title:
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Sponsor: Janssen
Indentifier #: NCT01877915
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure COMMANDER HF Study
Department: Cardiology
Diagnosis: Miscellaneous
Sub-Investigator(s):
Sponsor: Synageva
Indentifier #: NCT02112994
Title: A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01968967
Title: B1481020, A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS – SPIRE LDL
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975376
Title: B1481022: Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975389
Title: B1481038 PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Sub-Investigator(s):
Sponsor: Sanofi Aventis
Indentifier #: NCT01663402
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey SA_EFC11570)
Department: Cardiology
Diagnosis: Miscellaneous
Sub-Investigator(s):
Sponsor: Synageva
Indentifier #: NCT02112994
Title: A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01968967
Title: B1481020, A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS – SPIRE LDL
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975376
Title: B1481022: Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975389
Title: B1481038 PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Sub-Investigator(s):
Sponsor: Sanofi Aventis
Indentifier #: NCT01663402
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey SA_EFC11570)
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Sponsor: Janssen
Indentifier #: NCT01877915
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure COMMANDER HF Study

Publications